DDrare: Database of Drug Development for Rare Diseases

Trehalose (DrugBank: Trehalose)

2 diseases

ID	Disease name (Link within this page)	Number of trials
18	Spinocerebellar degeneration	0
113	Muscular dystrophy	1

18. Spinocerebellar degeneration [ 59 clinical trials, 78 drugs, (DrugBank: 28 drugs), 44 drug target genes, 59 drug target pathways]

Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.

0 / 59 trial found

113. Muscular dystrophy [ 567 clinical trials, 442 drugs, (DrugBank: 93 drugs), 55 drug target genes, 151 drug target pathways]

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 567 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226924 (ClinicalTrials.gov)	June 15, 2017	15/7/2019	Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Trial of Trehalose for the Treatment of	Oculopharyngeal Muscular Dystrophy	Drug: Trehalose	Bioblast Pharma Ltd.	NULL	Withdrawn	50 Years	70 Years	All	0	Phase 2	Canada